Health
Health|Pfizer’s TUKYSA Regimen
Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved TUKYSA® (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unrese…
October 7, 2026 · 12:57 PM Health
Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo
Pfizer Inc. (NYSE: PFE) today presented results from two Phase 3 trials evaluating the efficacy and safety of LITFULO® (ritlecitinib) as a once-daily oral treatment across a wide range of disease extent. In the two studi…
October 2, 2026 · 11:15 AM Health
Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study
Pfizer Inc. (NYSE: PFE) today presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-to-severe atopic dermatitis (AD). The study met its primary endpoint,…
October 1, 2026 · 2:30 AM Health
Pfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMO
Pfizer Inc. (NYSE: PFE) will present data from 45 company-sponsored, investigator-sponsored, and collaborative research abstracts at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27,…
September 28, 2026 · 6:45 AM
Health
Promising New Studies: SpinalSyn Offers Hope for Back Pain Relief
A randomized study involving 240 adults finds substantial improvements in pain and daily function with SpinalSyn.
September 1, 2025Latest from leading organizations
Explore recent announcements by organization
